PubMed Health⌕ Search

Biomedical subjects

H Gulliksson

Publications and source records attributed to H Gulliksson.

At least 19 recordsLinked to original sources
PubMed2005

Interruption of agitation of platelet concentrates: effects on in vitro parameters.

BACKGROUND AND OBJECTIVES: When platelet concentrates (PCs) are shipped from one centre to another, they may remain unagitated for a considerable period of time. It was therefore our aim to study the effects of interruption of agitation on the in vitro parameters of PCs stored in platelet additive solutions. MATERIALS AND METHODS: In this multicentre study, PCs were prepared either by apheresis or from pooled buffy coats, paired to minimize donor-dependent differences, and aliquoted into 3 units with a 'low concentration' (approximately 1 x 10(9) platelets/ml; groups A, B and C) and 3 units with a 'high concentration' (approximately 2 x 10(9) platelets/ml; groups D, E and F). The final composition of the storage medium was 30% plasma and 70% additive solution in all PCs. Either PASIIIM or Composol was used as the additive solution. Agitation was interrupted for 2 days (between days 3 and 5, groups A and D), or for 4 days (between days 1 and 5, groups B and E), and continuous agitation served as the reference (groups C and F). A number of in vitro parameters were used for testing on days 1, 5 and 7. RESULTS: On day 7, reference units C and F in PASIIIM had significantly higher pH values than the study units in PASIIIM, but all retained a pH of > 6.5 at 37 degrees C. Hypotonic shock response (HSR) results were significantly lower in the high concentration/4-day interruption group (E) than in the other groups. The low-concentration groups in PASIIIM, with agitation interrupted for either 2 days (group A) or 4 days (group B), did not have HSR values significantly different from the respective references. Study groups A, B, D and E in Composol, a solution lacking phosphate, had a pH of approximately 6.5 on day 7, which was significantly lower than that of the references and of the corresponding units in PASIIIM. The pH values were > 7.0 in reference groups C and F in Composol, not significantly different from those in PASIIIM. HSR values were also significantly lower in the Composol study groups. On the other hand, the reference Composol groups showed results similar to units in PASIIIM. CONCLUSIONS: PCs in PASIIIM additive solution with a platelet concentration of approximately 1 x 10(9)/ml can sustain 4 days without agitation. Phosphate may be of importance in maintaining good in vitro characteristics during interruption of agitation.

Blood Platelets↗
PubMed2005

Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system.

BACKGROUND: The aim was to evaluate platelet concentrates (PCs) prepared by the automated OrbiSac system, from pooled buffy coats (BCs) stored in a platelet (PLT) additive solution. STUDY DESIGN AND METHODS: Experiment 1 was a paired in vitro study of PCs (from six BCs), prepared by automated and manual procedures. Experiments 2 and 3 evaluated PCs from OrbiSac (from six BCs); Experiment 3 included selection of BCs based on donor data. Experiment 4 was a paired in vitro study of PCs (from six BCs) with an integrated white blood cell (WBC) filter and two different storage containers. Experiment 5 evaluated PCs (from six BCs) from the OrbiSac with an integrated WBC filter. Experiment 6 was similar to Experiment 5 with computer-selected pools of 5 BCs. The in vitro studies evaluated the effects of 7-day storage of PLTs regarding PLT metabolism and disintegration. RESULTS: Experiments 1 and 4 had similar in vitro results. In Experiment 2, PLT content was 370 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs was 76 +/- 6 percent. In Experiment 3, the PLT content was 380 x 10(9) +/- 50 x 10(9) per PC and variation was reduced compared with randomly pooled BCs. In Experiment 5, increased PLT content was found (420 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs of 80 +/- 5%). In Experiment 6, five rather than six BCs gave 340 x 10(9) +/- 60 x 10(9) PLTs per PC and recovery was 79 +/- 5 percent. CONCLUSION: These in vitro studies suggest that the OrbiSac technique is equivalent to the standard manual method regarding the PLT in vitro characteristics during storage for 7 days. The results of standardizing the PLT count in PCs by selecting the BCs pools on the basis of the blood donor PLT concentration were encouraging.

Blood Component Removal↗
PubMed2004

Platelet storage solution affects on the accuracy of laboratory tests for platelet function: a multi-laboratory study.

BACKGROUND AND OBJECTIVES: Extent of shape change (ESC) and hypotonic shock response (HSR) have been widely used to characterize the in vitro function of platelets and have been shown to correlate with in vivo viability. These assays have been routinely performed using platelet-poor plasma (PPP) as the test sample diluent. Because of the increasing popularity of storing platelets in synthetic media, it is important to understand the effects of using these synthetic media as test diluents for ESC and HSR measurements. The objective of this study was to determine the effect of using platelet storage solutions vs. plasma for the in vitro testing of ESC and HSR. MATERIALS AND METHODS: Six laboratories participated in this study. Platelets were prepared by apheresis, the platelet-rich plasma (PRP) method, or derived from buffy-coats. Each platelet preparation was divided, half being stored in plasma and the other half in storage solution. ESC and HSR testing were performed in duplicate on days 1 and 5, using each of three diluents: autologous plasma; fresh-frozen plasma; or storage solution. RESULTS: For both ESC and HSR, dilutions made in each of the three diluents yielded significantly different results. Dilutions made in storage solutions were more than 30% lower for ESC and HSR than those made in autologous plasma (P < 0.0001). Dilutions made in thawed fresh-frozen plasma were more than 16% lower for ESC and HSR than those made in liquid autologous plasma (P < 0.0005). CONCLUSIONS: ESC and HSR test results are significantly affected by the test diluent. Platelets should be diluted in plasma (preferably autologous) for the in vitro testing of ESC and HSR, regardless of the media in which they are stored.

Blood Platelets↗
PubMed2004

Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.

Despite the introduction of platelet additive solutions for the preparation of pooled platelet components, only a few studies of limited scope have evaluated the clinical efficacy of platelets stored in these solutions. The current report presents an analysis of data to evaluate the response to the transfusion of pooled buffy-coat components suspended in storage solution with reduced (35%) plasma content in comparison with 100% plasma products. During the euroSPRITE clinical trial of platelet components treated with a pathogen inactivation process, control treatment group platelet components were prepared in 100% allogeneic donor plasma (plasma control) or in platelet additive solution (T-Sol) mixed with plasma (T-Sol control). Control group thrombocytopenic patients received either plasma control or T-Sol control platelet components. One-hour and 24-h platelet count increments (CIs) and corrected count increments (CCIs) were analysed for these two types of preparation. In addition, haemostatic assessments were conducted for each transfusion. One-hour and 24-h mean platelet CIs and post-transfusion haemostatic scores were not significantly different for patients receiving platelet components suspended in 100% plasma and T-Sol plasma mixtures. Pooled buffy-coat platelet components prepared in reduced plasma content mixtures provided therapeutic platelet CIs with effective haemostasis.

Blood Component Transfusion↗
PubMed2003

In vivo and in vitro comparison of platelets stored in either synthetic media or plasma.

Since 1980, several synthetic media have been developed for the storage of platelets for transfusion. At present, platelets suspended in approximately 70% synthetic medium and 30% plasma can be stored for at least 5 days at very stable pH levels, generally pH 6.8-7.2. Present knowledge suggests that synthetic media should contain at least acetate, citrate, phosphate, potassium and magnesium. Future studies will probably result in the inclusion of other components to this list. Glucose for platelet metabolism will generally be supplied by carryover of plasma from the original platelet preparation. In addition, improved plastic containers for the storage of platelets will probably facilitate the introduction of new synthetic media. In six studies comparing synthetic media with plasma as the storage environment, and involving patients with intensive chemotherapy for haematological malignancies, the clinical outcome in terms of corrected count increments (CCI) generally indicated similar results. Three studies suggested significant reduction of the incidence of transfusion reactions of platelets suspended in synthetic media as compared with plasma. For future comparisons of platelet storage in either plasma or new synthetic media, additional platelet survival and recovery studies, as well as patient-transfusion studies, will be needed as in vitro data may not always reflect the clinical outcome. This will add further knowledge to data from the present few clinical studies available that compare storage of platelets in either synthetic media or plasma.

Blood Platelets↗
PubMed2003

Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium.

BACKGROUND AND OBJECTIVES: In a preliminary study, the presence of potassium and magnesium in a modified synthetic medium (PAS-III) was found to have a significant influence on platelet metabolism (using apheresis-derived, as well as buffy-coat-derived platelets) when compared with standard PAS-III. The differences included reduced glycolysis, as evidenced by lower consumption of glucose and lower production of lactate, but also better preservation of pH and hypotonic shock response reactivity. The results suggested that storage in modified PAS-III containing 20% plasma was comparable to storage in standard PAS-III containing 30% plasma. To confirm the preliminary results and to evaluate the effects of different preparation protocols, an international multicentre study, which included 11 different sites, was conducted. MATERIALS AND METHODS: Platelets from 30 pools of approximately 20 buffy coat (BC) units each and 24 pooled apheresis platelet units were aliquoted for storage in plasma (reference) or synthetic medium using either a specific additive solution (PAS-III) containing 30% plasma or a modification of PAS-III containing 5.0 mm potassium and 1.5 mm magnesium (PAS-IIIM) and either 30% or 20% plasma. Units were stored at room temperature with agitation for 7 days during which in vitro testing was carried out for biochemical, haematological and functional parameters. RESULTS: Storage of platelets in PAS-IIIM resulted in a reduction in the rate of glycolysis and better retention of pH and hypotonic shock response reactivity. Storage in PAS-IIIM containing 20% plasma appeared to result in the retention of in vitro properties, similar to those observed during storage in standard PAS-III containing 30% plasma. CONCLUSIONS: The results of this study confirm the preliminary results. Similar results were seen with platelets prepared by BC and apheresis methods, despite differences in equipment, the preparation technique and in the final platelet contents achieved in the platelet units. Storage of platelets in PAS-IIIM should be considered to improve platelet function and allow plasma reduction to 20%.

Blood Component Removal↗
PubMed2003

Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor 4 and interleukin-7, during storage.

BACKGROUND AND OBJECTIVES: Several studies have suggested that the accumulation of cytokines during storage of platelet concentrates may mediate non-haemolytic transfusion reactions. Prestorage leucodepletion can prevent the release of cytokines from white blood cells during storage, but not the release of platelet-derived cytokines. Therefore, we investigated whether the addition of magnesium and potassium to platelets stored in a platelet additive solution (PAS) would affect the generation of cytokines during platelet storage. MATERIALS AND METHODS: Platelets were prepared from buffy coats using different suspension media: plasma; 70% PAS-III + 30% plasma; 70% PAS-III supplemented with magnesium and potassium +30% plasma; and 80% PAS-III supplemented with magnesium and potassium +20% plasma. The levels of certain cytokines--regulated on activation, normal, T-cell expressed, and secreted (RANTES), beta-thromboglobulin (beta-TG), platelet factor 4 (PF4) and interleukin-7 (IL-7)--were measured by enzyme-linked immunosorbent assay (ELISA) on days 1, 5 and 7. RESULTS: The concentrations of RANTES, beta-TG, PF4 and IL-7 increased, during storage, in all units. The increase was significantly greater in units stored in 70% PAS-III +30% plasma than in the other three suspension media. The storage of platelets in 70% PAS-III supplemented with magnesium and potassium +30% plasma significantly reduced the concentrations of platelet derived-cytokines during storage, as compared to platelets stored in 70% PAS-III + 30% plasma alone. CONCLUSIONS: The concentrations of platelet-derived cytokines increased, to a significantly greater extent, when platelets were stored in PAS-III than in plasma. However, when magnesium and potassium were added to PAS-III, the concentrations of platelet-derived cytokines obtained during storage were about the same as those produced by platelets stored in plasma.

Blood Platelets↗
PubMed2002

Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium.

BACKGROUND AND OBJECTIVES: Platelet additive solutions (PAS) have been shown to be suitable for extended platelet storage but have required the carryover of substantial (30%) amounts of plasma for success. Improving platelet quality by optimizing the composition of PAS may allow a reduction to be made in the amount of plasma carried over. Reducing the proportion of plasma carried over would facilitate some methods of viral inactivation and make available greater amounts of plasma for other needs. MATERIALS AND METHODS: Platelets from six pools of 25 buffy coat platelet units and five apheresis platelet units were aliquoted for storage in plasma, or converted to PAS units in either a specific additive solution (PAS-III), with 30% or 20% plasma, or a modification of PAS-III containing 5.0 mm potassium and 1.5 mm magnesium (PAS-IIIM), with 30% or 20% plasma. Units were stored at room temperature with agitation for 7 days with in vitro testing for biochemical, haematological and functional parameters. RESULTS: Storage of platelets in PAS-IIIM resulted in a reduced rate of glycolysis and better retention of pH, morphology score and ATP levels. Platelets initially showed less evidence of activation when stored in PAS-IIIM, with reduced P-selectin expression. Storage in PAS-IIIM with 20% (rather than the standard 30%) plasma appeared to result in the retention of in vitro properties, similarly to storage in standard PAS-III with 30% plasma. CONCLUSIONS: Storing platelets in an additive solution containing magnesium and potassium improves the functionality of the platelets, as measured by in vitro testing, and may allow a reduction of the amount of plasma required to be carried over to the final unit.

Adenosine Triphosphate↗
PubMed2001

Platelet storage media.

Platelet additive solutions (PASs) can be used as a substitute for plasma for the storage of platelet concentrates (PCs) in order to recover plasma for other purposes, to avoid transfusion of large volumes of plasma to patients, to improve storage conditions, and to make possible photochemical treatment for viral inactivation of PCs. The effects on platelet metabolism associated with different factors and compounds in PAS are only partly known. Available studies suggest that: (1) The presence of glucose in the platelet storage medium during the entire storage period is necessary for platelet metabolism. (2) Acetate is used as a substrate for platelet metabolism reducing production of lactate by platelets. By formation of bicarbonate, it maintains stable pH levels during storage. (3) The fall in pH can be rapid in PAS-containing media, due to the very limited buffering capacity of PAS compared with that of plasma. (4) Platelets stored in PAS at a citrate concentration of 8 mmol/l produce only half the quantity of lactate as that of platelets at 14-26 mmol/l of citrate. (5) Free fatty acids from plasma can be used as substrate for platelet metabolism and are supposed to be made available by the hydrolysis of plasma triglycerides. (6) For apheresis PCs with ACD anticoagulant, the presence of phosphate in PAS seems to be a critical factor to avoid low adenine nucleotide levels during storage. The results of available studies suggest that PAS for storing platelets has a great potential for wide use in transfusion medicine. A number of interesting questions regarding the effects of different compounds in PAS are still to be answered. It is expected that answers to these questions will be provided over the next few years.

Acetates↗
PubMed2001

Evaluation of a whole-blood WBC-reduction filter that saves platelets: in vitro studies.

BACKGROUND: In this study, a new WBC-reduction in-line filter that removes WBCs but not platelets was evaluated. Three WBC-reduced blood components were prepared: RBCs, plasma, and platelet concentrates (PCs). STUDY DESIGN AND METHODS: Whole-blood components (n = 30) were filtered within 2 to 4 hours after collection and then were centrifuged and separated into RBCs, plasma, and WBC-reduced buffy coat. Saline-adenine-glucose-mannitol solution was added to the RBCS: The WBC-reduced buffy coats were stored overnight; on the following day, PCs were prepared from pooled WBC-reduced buffy coats and stored in a medium composed of approximately 35 percent CPD plasma and 65 percent platelet additive solution (T-Sol, Baxter). The WBC-reduction capacity of the filter, the recovery of cells after filtration, and the in vitro storage of RBCs (n = 10) and platelets (n = 6) were evaluated. RESULTS: Mean and maximum WBC counts after filtration were 0.08 x 10(6) and 0.3 x 10(6), respectively, per filtered whole-blood unit. Recovery of RBCs (mean values) after filtration was 90 percent in whole-blood components and 73 percent in RBCS: Recovery of platelets (mean values) was 81 percent after filtration and 66 percent in PCS: The in vitro storage study of RBCs showed results comparable with previously published data, except for a lower degree of hemolysis. In the in vitro platelet storage study, results were compared with those of standard preparations. In all essentials, similar results were found. CONCLUSION: The results of the present study suggest that effective WBC reduction meets current standards and satisfactory recovery after filtration. The storage characteristics for RBCs and PCs are similar to those of standard preparations. Use of a whole-blood in-line filter to save platelets is a new option for whole-blood processing, which may simplify WBC reduction and blood component preparation, as well as reduce costs in the future.

Blood Component Removal↗
PubMed2000

Storage of platelets in additive solutions: effects of phosphate.

BACKGROUND AND OBJECTIVES: In a previous study, low adenine nucleotide levels and a reduced rate of glycolysis were found in platelet concentrates (PCs) prepared by apheresis and stored in a platelet additive solution (PAS). Our objective was to investigate whether the use of PAS with or without phosphate can influence platelet metabolism in a similar way. MATERIALS AND METHODS: The in vitro effects of storage in either plasma or a PAS (T-Sol or PAS-III, both containing citrate, acetate and sodium chloride, PAS-III containing also phosphate) of buffy-coat-derived pooled platelet concentrates (BC-PCs) and apheresis platelets were investigated. The use of PAS implies inclusion of some plasma (20 or 35%). Paired studies over 7 days included investigation of cell counts, pH, PO2, PCO2, bicarbonate, glucose, lactate, adenine nucleotides, and extracellular adenylate kinase activity as a marker for disintegration of platelets. The expected concentration of phosphate in T-Sol is 0.6-1.8 mmol/l (with CPD plasma) and 0.2-0.6 mmol/l (with ACD plasma), and in PAS-III, 15-25 mmol/l (calculated values). RESULTS: BC-PCs were compared during storage in 35% CPD plasma and 65% PAS (T-Sol or PAS-III) (experiment 1), or alternatively 20% CPD plasma and 80% PAS (T-Sol or PAS-III) (experiment 3). In both studies, PAS-III shows similar and significantly higher rates of glycolysis in terms of consumption of glucose (0.06 vs. 0.04 mmol/day/10(11) platelets) and production of lactate (0.11 vs. 0.07 mmol/day/10(11) platelets) compared with T-Sol. Levels of pH and adenine nucleotides were similar when 35% plasma was used. With only 20% plasma, significantly higher levels of adenine nucleotides were found with PAS-III compared to T-Sol. The storage of apheresis platelets in 35% ACD plasma and 65% PAS (either T-Sol or PAS-III) (experiment 5) gave significantly higher values for PAS-III compared to T-Sol with regard to consumption of glucose (0.08 vs. 0.06 mmol/day/10(11) platelets), production of lactate (0.14 vs. 0.11 mmol/day/10(11) platelets) and adenine nucleotide levels. CONCLUSION: With respect to apheresis PCs stored in media containing ACD plasma, our results suggest that the differences found are related to the concentration of phosphate. The results for BC-PCs stored in media containing CPD plasma suggest that PAS-III is preferable to T-Sol as the PAS at plasma concentrations below 35%. The mechanism behind the phenomena observed with BC-PCs is not known.

Blood Platelets↗
PubMed1997

A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis platelets.

Our objective was to create a system for the supply of platelet concentrates (PCs) based on leukocyte-filtered PCs suspended in a storage medium (PAS-II) including: (1) pooled buffy-coat-derived (BC) PCs and (2) "split" apheresis PCs. The same standards were intended for the two preparations with regard to composition and blood cell counts. In preliminary studies, similar in vitro data were found for leukocyte-filtered and non-filtered reference BC PCs. Slightly inferior in vitro results than for BC PCs restricted the shelf-life of apheresis PCs to 5 days compared to 7 days for BC PCs. With the present platelet supply system in use as a routine service for one year, the experience was very satisfactory, meeting the demands for PCs very efficiently and resulting in a low out-dating rate (5%).

Blood Platelets↗
PubMed1997

International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience.

The need for source material for plasma products such as factor VIII preparations and improving the quality of red cells for transfusion became determining factors in the choice of methods for blood components in the 1970s and 1980s in Sweden. The possibility to make platelet concentrates (PC) from buffy coats (BC-PC) instead of from platelet-rich plasma (PRP-PC), as first described in England and The Netherlands, using an additive solution as the major component of the platelet storage medium, as first described by Rock et al., has been shown to influence favourably the national supply of blood components and has become accepted as the normal standard procedure in the first half of the 1990s. Leucocyte-depleted PCs, produced from pools of 4-6 BCs, used in all multiple platelet transfusions to thrombocytopenic patients, have strongly reduced the demand for HLA compatible PCs. Nationwide, 79% of the demand of PCs is supplied as BC-PCs, mostly leuco-depleted which, so far, have compared favourably with apheresis-PCs for cost-effectiveness.

Blood Component Removal↗
PubMed1995

Buffy-coat-derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units. Comparison between three additive solutions: in vitro studies.

The in vitro effects of storage of platelets prepared from 4 or 6 pooled buffy coat (BC) units and stored in a platelet storage medium consisting of 30-40% of CPD plasma or alternatively half-strength citrate CPD (0.5 CPD) plasma and 60-70% of different alternative platelet additive solutions (PASs) were evaluated. Measurements of mean platelet volume, pH, pO2, pCO2, bicarbonate, glucose, lactate, ATP, total adenine nucleotide content, extracellular lactate dehydrogenase or adenylate kinase activity, as markers for disintegration of platelets, and extracellular beta-thromboglobulin, as a marker for activation of platelets, were included in the in vitro studies. Previous studies indicated that a reduction of the citrate concentration from the standard 21 to 8 mmol/l is associated with a significant reduction of the consumption of glucose and production of lactate. Alternatively, similar effects can be obtained by the addition of acetate. In a preliminary paired study, the effects of different concentrations of acetate were tested. In an additional paired study, the effects of CPD plasma in combination with either saline or a PAS containing NaCl (115.5 mmol/l), citrate (10 mmol/l), and acetate (30 mmol/l), pH 7.2 (PAS-2) were evaluated. 0.5CPD plasma in combination with either PAS-2 or a nonacetate PAS (PAS-1) were also tested. The storage of platelets in 0.5CPD plasma was used as a reference. The conclusions are: (1) A minimum acetate concentration of 30 mmol/l is needed to counteract the effects of citrate on the production of lactate. (2) pH and the bicarbonate buffering capacity are significantly better maintained in PAS-2 than in PAS-1.(ABSTRACT TRUNCATED AT 250 WORDS)

Anticoagulants↗
PubMed1993

Storage of platelets in additive solutions: the effect of citrate and acetate in in vitro studies.

The in vitro effects of storage of platelets prepared from 6 pooled buffy coat units and stored in a platelet storage medium consisting of CPD and plasma and different platelet additive solutions were evaluated. The total count of platelets per pooled unit included in the present investigation (n = 20) was 335 +/- 35 x 10(9) (mean +/- SD). Measurements of pH, pO2, pCO2, glucose, lactate, ATP, total adenine nucleotide content, and extracellular adenylate kinase activity were performed in a three-part study. The observations were 1) During storage in saline and citrate (10 mmol/L of citrate), the consumption of glucose and the production of lactate were significantly increased over the values with storage in saline, which were used as a reference. The values for pH at Day 6 were significantly lower. 2) The effects of different concentrations (10, 20, and 30 mmol/L) of acetate in saline were studied. With the exception of significantly higher pH values in saline and acetate, no significant differences were seen in the effects with saline and those with saline and acetate. 3) The combined effect of citrate and acetate was evaluated. The consumption of glucose and the production of lactate, the values for pO2, and extracellular adenylate kinase activity were significantly lower with saline and citrate and acetate than with saline and citrate. Significantly higher values for pH were found at Day 5.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetates↗
PubMed1993

Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies.

Leukocyte-depleted platelet concentrates were prepared from pools of 4 buffy coats on the day after blood collection (BC-PC). The storage medium was composed of citrate phosphate dextrose plasma and a platelet-additive solution. Autologous transfusions of 111In-labelled platelets in 9 healthy volunteers were performed on the day of preparation (day 1) and on day 5. The recovery was 54.6 +/- 8.7 (day 1) and 51.9 +/- 10.4% (day 5), T1/2 was 101 +/- 28 and 61 +/- 9 h, respectively. The survival was 8.3 +/- 1.7 and 5.7 +/- 1.0 days, respectively, using linear plot, and 7.8 +/- 2.0 and 5.8 +/- 0.5 days using the multiple hit method. In a prospective clinical study a comparison of the corrected posttransfusion increments was made between BC-PCs and apheresis-PC, and between fresh (1-2 days) and stored (3-5 days) preparations. No difference was found between BC-PCs and apheresis PCs. However, fresh BC-PCs gave higher increments than stored BC-PCs. A slight numerical difference between fresh and stored apheresis-PCs was not statistically significant. It is concluded that the BC-PC method results in platelets of equal quality to apheresis-PC.

Adult↗